Collegium Pharmaceutical (NASDAQ:COLL) Reaches New 1-Year Low – Should You Sell?

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) hit a new 52-week low on Thursday . The company traded as low as $23.84 and last traded at $24.30, with a volume of 852658 shares changing hands. The stock had previously closed at $24.00.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Zacks Research downgraded shares of Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a research note on Monday, June 15th. Barclays reduced their target price on shares of Collegium Pharmaceutical from $56.00 to $48.00 and set an “overweight” rating on the stock in a report on Wednesday, August 19th. Needham & Company LLC lowered their price target on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Finally, Weiss Ratings lowered Collegium Pharmaceutical from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.00.

Collegium Pharmaceutical Trading Down 0.7%

The business’s 50-day simple moving average is $31.86 and its two-hundred day simple moving average is $34.30. The company has a current ratio of 1.03, a quick ratio of 0.84 and a debt-to-equity ratio of 3.32. The company has a market capitalization of $766.04 million, a PE ratio of 18.98 and a beta of 0.72.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The business had revenue of $199.88 million for the quarter, compared to analyst estimates of $199.62 million. Collegium Pharmaceutical had a return on equity of 91.43% and a net margin of 5.93%.The company’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same period in the previous year, the company earned $1.68 earnings per share. On average, analysts predict that Collegium Pharmaceutical, Inc. will post 6.51 earnings per share for the current year.

Institutional Trading of Collegium Pharmaceutical

A number of hedge funds have recently made changes to their positions in COLL. BlackRock Inc. bought a new position in Collegium Pharmaceutical during the 2nd quarter valued at $196,972,000. Jupiter Topco LLC acquired a new position in Collegium Pharmaceutical during the 2nd quarter worth $77,743,000. California State Teachers Retirement System increased its position in shares of Collegium Pharmaceutical by 5,165.8% in the 2nd quarter. California State Teachers Retirement System now owns 1,550,410 shares of the specialty pharmaceutical company’s stock worth $56,125,000 after purchasing an additional 1,520,967 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Collegium Pharmaceutical by 59.1% in the 4th quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock worth $67,026,000 after purchasing an additional 538,337 shares during the last quarter. Finally, Millennium Management LLC raised its stake in shares of Collegium Pharmaceutical by 248.5% in the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock valued at $19,338,000 after purchasing an additional 461,914 shares in the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.